Cited by 294Cancer Genomics and DiagnosticsLung Cancer Treatments and MutationsBRCA gene mutations in cancer

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

Open access

Flaherty, Keith T., Gray, Robert J., Chen, Alice P., Li, Shuli, McShane, Lisa M., Patton, David, Hamilton, Stanley R., Williams, P. Mickey, Iafrate, A. John, Sklar, Jeffrey, Mitchell, Edith P., Harris, Lyndsay N., Takebe, Naoko, Sims, David J., Coffey, Brent, Fu, Tony, Routbort, Mark, Zwiebel, James A., Rubinstein, Larry V., Little, Richard F., Arteaga, Carlos L., Comis, Robert, Abrams, Jeffrey S., O’Dwyer, Peter J., Conley, Barbara A., for the NCI-MATCH team·2020·Journal of Clinical Oncology

DOI 10.1200/jco.19.03010PMC PMC7676882

Open this paper in CoChat — free account

Abstract

PURPOSE: Therapeutically actionable molecular alterations are widely distributed across cancer types. The National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial was designed to evaluate targeted therapy antitumor activity in underexplored cancer types. Tumor biopsy specimens were analyzed centrally with next-generation sequencing (NGS) in a master screening protocol. Patients with a tumor molecular alteration addressed by a targeted treatment lacking established efficacy in that tumor type were assigned to 1 of 30 treatments in parallel, single-arm, phase II subprotocols. PATIENTS AND METHODS: Tumor biopsy specimens from 5,954 patients with refractory malignancies at 1,117 accrual sites were analyzed centrally with NGS and selected immunohistochemistry in a master screening protocol. The treatment-assignment rate to treatment arms was assessed. Molecular alterations in seven tumors profiled in both NCI-MATCH trial and The Cancer Genome Atlas (TCGA) of primary tumors were compared. RESULTS: Molecular profiling was successful in 93.0% of specimens. An actionable alteration was found in 37.6%. After applying clinical and molecular exclusion criteria, 17.8% were assigned (26.4% could have been assigned if all subprotocols were available simultaneously). Eleven subprotocols reached their accrual goal as of this report. Actionability rates differed among histologies (eg, > 35% for urothelial cancers and < 6% for pancreatic and small-cell lung cancer). Multiple actionable or resistance-conferring tumor mutations were seen in 11.9% and 71.3% of specimens, respectively. Known resistance mutations to targeted therapies were numerically more frequent in NCI-MATCH than TCGA tumors, but not markedly so. CONCLUSION: We demonstrated feasibility of screening large numbers of patients at numerous accruing sites in a complex trial to test investigational therapies for moderately frequent molecular targets. Co-occurring resistance mutations were common and endorse investigation of combination targeted-therapy regimens.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.19.03010

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Maftools: efficient and comprehensive analysis of somatic variants in cancerPreprint
Mayakonda, A., Lin, D., Assenov, Y., Plass, C., & Koeffler, H. P. (2018) · Genome Research · doi:10.1101/gr.239244.118 · Cited by 5,005
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Self-citation
circlize implements and enhances circular visualization in R
Gu, Z., Gu, L., Eils, R., Schlesner, M., & Brors, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu393 · Cited by 4,290
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“7) Median age, years (range) 62 (18-94) 62 (18-94) 62 (18-92) 61 (19-85)”
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. E. D. C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,521

Flagged first, then by citations

Show all 27 references

Sorted by citations

Items 201–293 of 293

The Evolving Role for Repeat Molecular Testing in Metastatic Colorectal Cancer
Kendsersky, N. D., Erlick, M. R., Chen, E., & Kennecke, H. F. (2026) · Cancers · doi:10.3390/cancers18061007 · Cited by 2
A single-institution retrospective study of comprehensive genomic profiling tests based on C-CAT findings for advanced solid cancers
Takeuchi, S., Yoshimura, A., Sofuni, A., Ueda, Y., Umezu, T., Kuroda, M., Sukeda, A., Matsubayashi, J., Nagao, T., Bingo, M., et al. (2024) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyae128 · Cited by 2
Analysis of actionable gene fusions in a large cohort of Chinese patients with colorectal cancer
Kou, F.-R., Li, J., Wang, Z., Xu, T., Qian, J.-J., Zhang, E.-L., Zhang, L., Shen, L., & Wang, X. (2023) · Gastroenterology report · doi:10.1093/gastro/goae092 · Cited by 2
Single whole genome sequencing analysis blazes the trail for precision medicine
Napoli, G. C., Chau, C. H., & Figg, W. D. (2022) · Cancer Biology & Therapy · doi:10.1080/15384047.2022.2033058 · Cited by 2
Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT
Brown, L. C., Fisher, D. J., Adams, R., Seligmann, J. F., Seymour, M., Kaplan, R. S., Richman, S. D., Quirke, P., Butler, R., Roberts, H. C., et al. (2022) · Efficacy and Mechanism Evaluation · doi:10.3310/htnb6908 · Cited by 2
Functional precision oncology: bridging genotypes and phenotypes
Wu, X., Zhu, Y., & Huang, J. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-1363 · Cited by 1
Pazopanib elicits remarkable response in metastatic porocarcinoma: a functional precision medicine approachPreprint
Chan, S. P. Y., Low, C. E., Yau, C. E., Lin, T. P., Wang, W., Sam, X. X., Tang, P. Y., Luo, B., Noor, N. F. B. M., Lee, K. A., et al. (2023) · Molecular Case Studies · doi:10.1101/mcs.a006308 · Cited by 2
rBMA: A robust Bayesian Model Averaging Method for phase II basket trials based on informative mixture priors
Wang, X., & Wei, W. (2024) · Contemporary Clinical Trials · doi:10.1016/j.cct.2024.107505 · Cited by 1
A Cross-Sectional Study of Variant Interpretation and Reporting of NGS Data Using Tertiary Analysis Software: Navify® Mutation Profiler
Pepe, F., Russo, G., Barraco, N., Bono, M., Listì, A., Righi, L., de Biase, D., Maloberti, T., Scimone, C., Palumbo, L., et al. (2024) · Oncology and Therapy · doi:10.1007/s40487-024-00316-0 · Cited by 1
Technological advances in clinical individualized medication for cancer therapy: from genes to whole organism
Kai, J., Liu, X., Wu, M., Liu, P., Lin, M., Yang, H., & Zhao, Q. (2025) · Personalized Medicine · doi:10.1080/17410541.2024.2447224 · Cited by 3
Biomarker Testing in Advanced Cancer
Kehl, K. L. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.19972 · Cited by 1
Somatic mutations in Middle East and North Africa breast cancer patients: a systematic review
Abujamous, L., Ahmed, I., Ahen, Y., Alotaibi, H., Moustafa, A. A., Arif, S. M., Al-Thawadi, H., & Razali, R. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf205 · Cited by 2
Clinical significance of comprehensive genomic profiling in unresectable or recurrent gastrointestinal stromal tumors: a multicenter retrospective cohort study
Kawabata, K., Takahashi, T., Hara, H., Kurokawa, Y., Yamamoto, K., Saito, T., Akamaru, Y., Motoori, M., Nishida, T., Hirota, S., et al. (2025) · Journal of Gastroenterology · doi:10.1007/s00535-025-02327-8 · Cited by 1
Genomics of ovarian cancers and the potential of precision medicine
Jarratt, A., Polidano, J., Scott, C. L., & Barker, H. E. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251396651 · Cited by 1
Non-small cell lung cancer research: advances and persistent challenges
Zhou, L., & Jiang, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1729747 · Cited by 1
Molecular Tumor Boards clinical impact on patient care and structural features: A systematic review and meta-analysis
Russo, L., Giacobini, E., Lentini, N., Osti, T., Kamal, M. T., Boccia, S., & Pastorino, R. (2026) · PLoS Medicine · doi:10.1371/journal.pmed.1005125 · Cited by 1
Federal and Industry Sponsorship in US Cancer Clinical Trials
Unger, J. M., Xiao, H., LeBlanc, M. L., & Hershman, D. L. (2026) · JAMA Oncology · doi:10.1001/jamaoncol.2026.3026 · Cited by 1
Confirmatory prediction-driven RCTs in comparative effectiveness settings for cancer treatment
Brand, A., Sachs, M. C., Sjölander, A., & Gabriel, E. E. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02144-x · Cited by 1
Transactivation of Met signaling by oncogenic Gnaq drives the evolution of melanoma in Hgf-Cdk4 mice
Mengoni, M., Braun, A. D., Seedarala, S., Bonifatius, S., Kostenis, E., Schanze, D., Zenker, M., Tüting, T., & Gaffal, E. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00744-0 · Cited by 1
Changes in Daily Apparent Diffusion Coefficient on Fully Quantitative Magnetic Resonance Imaging Correlate With Established Genomic Pathways of Radiation Sensitivity and Reveal Novel Biologic Associations
Hall, W. A., Mathison, A., DeVoe, E., Tschannen, M., Wendt-Andrae, J., Straza, M. W., Awan, M., Puckett, L. L., Lawton, C. A. F., Schultz, C., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.03.042 · Cited by 1
Reproducing the normal and the pathological in personalized cancer medicine clinical trials
Chorev, N. E., & Filc, D. (2024) · BioSocieties · doi:10.1057/s41292-024-00329-y · Cited by 1
Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies
Gupta, D., Kurzrock, R., Lee, S., Okamura, R., Lim, H. J., Kim, K. H., Sicklick, J. K., & Kato, S. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00259-7 · Cited by 1
Personalised pharmacotherapy options for soft tissue sarcomas
Arifi, S. (2022) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2022.2038562 · Cited by 1
The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group ( TOG ) study
Güven, D. C., Aykan, M. B., Muğlu, H., Bayram, E., Helvacı, K., Dursun, B., Celayir, M., Celebiyev, E., Nayır, E., Erman, M., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6869
Accuracy of somatic variant detection workflows for whole genome sequencing experimentsPreprint
Jaksik, R., Rosiak, J., Zawadzki, P., & Sztromwasser, P. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.10.446467 · Cited by 1
Kinome focused CRISPR-Cas9 screens in African ancestry patient-derived breast cancer organoids identify essential kinases and synergy of EGFR and FGFR1 inhibitionPreprint
Martín, M. L., Martini, R. N., Ackermann, S. E., Tang, C., Tranquille, M., Irizarry, A., Us, I., Alawa, O., Moyer, J. E., Sigouros, M., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3857407/v1 · Cited by 1
Genomic testing and patient rights
Jones, C. M., Karp, J. E., & Davis, D. S. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae043 · Cited by 1
A precision oncology-focused deep learning framework for personalized selection of cancer therapyPreprint
Sederman, C., Yang, C., Cortes-Sanchez, E., DiSera, T., Huang, X., Scherer, S. D., Zhao, L., Chu, Z., White, E. R., Atkinson, A. E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.12.628190 · Cited by 4
Matched sequential tumor molecular profiling in solid malignancies may impact clinical practice
Lai, T. S., Manrriquez, E. N., Neal, A. S., & Memarzadeh, S. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.12.008
Cancer Genomic Profiling of Gynecological Malignancies by Todai OncoPanel, a Twin DNA and RNA Panel
Tanikawa, M., Kage, H., Kohsaka, S., Tatsuno, K., Ushiku, T., Miyagawa, K., Aburatani, H., Mano, H., & Oda, K. (2021) · Current human cell research and applications · doi:10.1007/978-981-33-6013-6_3
Agnostische Tumortherapie – was ist das?
Schmidt, M., Hönig, A., Denkert, C., & Desuki, A. (2021) · Der Gynäkologe · doi:10.1007/s00129-021-04788-3
Introducing the Ongoing Clinical Trials in the Surgical Oncology Series
Hernandez, J. M., & McMasters, K. M. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10113-y
Editorial: Next-Generation Cancer Therapies Based on a (R)evolution of the Biomarker Landscape
Cerella, C., Lorant, A., Aquilano, K., & Diederich, M. F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.861424
Indications and pivotal trials of the FDA approved small-molecular kinase inhibitors in cancer therapies with and without biomarker of cancer driver genePreprint
Huang, Y., Xiong, W., Ma, L., & Wu, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1443724/v1
Molecularly Targeted Therapy in Cholangiocarcinoma
Desai, A. P., & Borad, M. J. (2022) · Springer eBooks · doi:10.1007/978-981-19-0063-1_22
Pediatric precision oncology—Time for clinical prime time
Pfister, S. M., Witt, O., & Jones, D. (2022) · Med · doi:10.1016/j.medj.2022.07.004
How Genome-Wide Analysis Contributes to Personalized Treatment in Cancer, Including Gynecologic Cancer?
Takaya, H. (2022) · Comprehensive gynecology and obstetrics · doi:10.1007/978-981-19-4711-7_8
Identification of targetable genomic profiling of breast cancer brain metastases identifies alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitorsPreprint
Palmieri, C., Giannoudis, A., Sokol, E. S., Bhogal, T., Ramkissoon, S. H., Razis, E. D., Bartsch, R., Shaw, J., McGregor, K., Clark, A. P., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2484456/v1
Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Meric‐Bernstam, F., Ford, J. M., O'Dwyer, P. J., Shapiro, G. I., McShane, L. M., Freidlin, B., O'Cearbhaill, R. E., George, S., Bender, J. G., Lyman, G. H., et al. (2023) · doi:10.1158/1078-0432.c.6533210.v1
Self-citation
Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Meric‐Bernstam, F., Ford, J. M., O'Dwyer, P. J., Shapiro, G. I., McShane, L. M., Freidlin, B., O'Cearbhaill, R. E., George, S., Bender, J. G., Lyman, G. H., et al. (2023) · doi:10.1158/1078-0432.c.6533210.v2
Self-citation
Functional Personalized Treatment of Metastatic PorocarcinomaPreprint
Chan, S. P. Y., Low, C. E., Yau, C. E., Lin, T. P., Wang, W., Sam, X. X., Tang, P. Y., Luo, B., Noor, N. F. B. M., Lee, K. A., et al. (2023) · medRxiv · doi:10.1101/2023.05.09.23289625
Data from Optimizing precision medicine for breast cancer brain metastases with functional drug response assessment.
Morikawa, A., Li, J., Ulintz, P., Cheng, X., Apfel, A. M., Robinson, D. R., Hopkins, A., Kumar‐Sinha, C., Wu, Y., Serhan, H. A., et al. (2023) · doi:10.1158/2767-9764.c.6689056.v1
Data from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment
Morikawa, A., Li, J., Ulintz, P., Cheng, X., Apfel, A. M., Robinson, D. R., Hopkins, A., Kumar‐Sinha, C., Wu, Y., Serhan, H. A., et al. (2023) · doi:10.1158/2767-9764.c.6689056
Biomarkers determining treatment tactics in metastatic urothelial cancer
Grivtsova, L. Y., Karyakin, O. B., Syadrin, M. G., Samborsky, S. M., Иванов, С. А., & Каприн, А. Д. (2023) · Cancer Urology · doi:10.17650/1726-9776-2023-19-2-111-126
Author comment: Heterogeneity in precision oncology — R0/PR1
Jassem, J. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.23.pr1
Decision: Heterogeneity in precision oncology — R1/PR8
(2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.23.pr8
Review: Heterogeneity in precision oncology — R1/PR6
Tomasik, B., Garbicz, F., Braun, M., et al. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.23.pr6
Recommendation: Heterogeneity in precision oncology — R0/PR3
Tomasik, B., Garbicz, F., Braun, M., et al. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.23.pr3
Decision: Heterogeneity in precision oncology — R0/PR4
Tomasik, B., Garbicz, F., Braun, M., et al. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.23.pr4
Recommendation: Heterogeneity in precision oncology — R1/PR7
Tomasik, B., Garbicz, F., Braun, M., et al. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.23.pr7
Review: Heterogeneity in precision oncology — R0/PR2
(2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.23.pr2
Author comment: Heterogeneity in precision oncology — R1/PR5
Jassem, J. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.23.pr5
The Changing Landscape of Cancer Treatment
Ko, H. C., Chang, E., Canola, M. M., Tao, Z., Hughes, D., Nelson, K., & Siegel, T. (2024) · doi:10.1093/oso/9780197607299.003.0002
Genomic Profiling of Breast Cancer: A Single Institution's Experience and Impact on Patient Outcomes
Ibrahim Ezzelkdin, M., Al-Quzi, B. A., Jabal Duaa, A., Bayer Ali, M., Shaheen Ahmed, Y., Morsi Zeinab, A., Ahmed Majidah, M., Kulak Mohammed, H., & Refae Ahmed, A. (2024) · International Journal of Cancer and Clinical Research · doi:10.23937/2378-3419/1410185
A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol
Neal, J. W., Minichiello, K., Brennick, R. C., Huang, R. S. P., Hiemenz, M., Amler, C., Patel, J. D., Herbst, R. S., Reckamp, K. L., Borghaei, H., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae062
Comprehensive genomic profiling of Taiwanese triple negative breast cancers with medium- and large-sized sequencing panels: a comparative study of actionable genesPreprint
Huang, C., Yeh, Y., Tsai, Y., Lin, Y., Chao, T., Liu, C., Ho, H., & Tseng, L. (2024) · Research Square · doi:10.21203/rs.3.rs-4638838/v1
Pharmacoproteomics and Cancer Management
Amoafo, E. B., Twum, E., Dankyi, B. O., Quaye, B., Amponsah, S. K., & Opuni, K. F. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-64021-6_8
SAEG: A Novel Deep Learning Architecture for Somatic AlterationsPreprint
Iglesias-Martinez, L. F., Wester, D. Y., & Kölch, W. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.21.639424
High Content Imaging Applications of Advanced and Translational Disease Models in Drug Discovery and Development
Cui, W., Haffa, M., Massai, F., Qian, K., Vallin, M., Axelsson, H., & Seashore-Ludlow, B. A. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837676941-00168
Precision Medicine Beyond Genomics
Bray, T., & Sanz‐García, E. (2025) · Springer eBooks · doi:10.1007/978-3-031-84539-0_7
Single-Cell Microwave Cytometry for Drug Resistance Detection in CancerPreprint
Tefek, U., Alhmoud, H. Z., Chau, T., Salehin, S., Yalçın, G. D., Saatci, Ö., Ulukan, B., Auerbach, S., Puka, B., Acar, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.24.661288
Clinical utility and characteristics of comprehensive genomic profiling tests in patients with gynecologic cancer: a multi-institutional survey in Kinki District, Japan
Terada, S., Tanaka, T., Hisamatsu, Y., Kita, M., Taki, M., Yamanoi, K., Fujita, H., Kato, S., Kataoka, H., Mori, T., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02835-w
Determination of Drug Sensitivity in Patient Derived Models of Breast Cancer by Multiparametric QPIPreprint
Polanco, E. R., Moustafa, T. E., Balcioglu, O., Scherer, S. D., Cortes-Sanchez, E., Remick, S., Spike, B. T., Welm, A. L., Welm, B. E., Bernard, P. S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.01.674349
Impact of next-generation sequencing on routine clinical practice and patient inclusion in molecularly targeted clinical trials: a retrospective cohort analysis
Faigner, M., Karayan, L., Cortes, U., Ndiaye, B., Martel, M., Rivet, P., Duche, J., Isambert, N., Tougeron, D., & Evrard, C. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04086-7
Evaluation of antileukemic potentials of maslinic acid through targeting responsive proteins of human leukemia: a mechanistic perception on molecular modelling and dynamic stimulations
Banerjee, J., Samanta, S., Afiadenyo, M., Ahmed, R., Das, S., Hasan, S. N., & Dash, S. K. (2025) · In Silico Pharmacology · doi:10.1007/s40203-025-00478-3
Additional file 1 of Clinical impact of panel gene sequencing on therapy of advanced cancers of the digestive system: a retrospective, single center study
Dreikhausen, L., Klupsch, A., Wiest, I., Xiao, Q., Schulte, N., Betge, J., Boch, T., Brochhausen, C., Gaiser, T., Hofheinz, R.-D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26712305
Additional file 1 of Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: a phase 2, single-center, open-label, and non-comparative study
Jensen, L. H., Rogatto, S. R., Lindebjerg, J., Havelund, B. M., Abildgaard, C., do Canto, L. M., Vagn-Hansen, C., Dam, C., Rafaelsen, S. R., & Hansen, T. F. (2023) · Figshare · doi:10.6084/m9.figshare.22767471
Clinical Utility of Comprehensive Genomic Profiling in a Community Hospital Outside the Cancer Genomic Core Hospital Network: A Single-Center Retrospective Cohort Study
Sasaki, A., & Kimura, R. (2026) · Cureus · doi:10.7759/cureus.101510
Recent advances in detection techniques regarding predictive, prognostic, and diagnostic biomarkers in solid cancers and its future challenges
Tripathy, S., Gaur, A., Jagadeb, M., Swarup, V., Gupta, N. M., Kumar, U., Das, S., & Jana, M. K. (2026) · Advances in cancer research · doi:10.1016/bs.acr.2025.12.006
Innovative Research Organization to Facilitate Clinical Trials Implementation in the Era of Molecular Oncology: The Spiderweb Model of the Oncodistinct Network
Nannini, S., Gonçalvès, A., Gomez‐Roca, C., Papamichael, D., Idrissi, I. E., Awada, A. H., Kotecki, N., & OncoDistinct Network (2026) · JCO Precision Oncology · doi:10.1200/po-25-00953
Assessing the Impact of Comprehensive Genomic Profiling on Therapeutic Selection for Advanced Solid Tumors in Portugal
Tavares, N. T., Simões, P., Lopes-Brás, R., Pacheco, T. R., Dâmaso, S., Mansinho, A., Ribeiro, L. A., Nogueira-Costa, G., Abreu, C., Barroso, T., et al. (2026) · Current Oncology · doi:10.3390/curroncol33020066
Ex vivo drug testing in metastatic biopsies reveals patient-specific vulnerabilities to cancer targeting and immune activating drugsPreprint
Wöhrl, L., Das, D., Weidele, K., Treitschke, S., Baron, C., Halbritter, D., Botteron, C., Lüke, F., Gužvić, N. S., Werner‐Klein, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.06.704037
Establishment of a Large‐Scale PDX Library of Head and Neck Cancers for Functional Precision Oncology
Yanagi, H., Kuki, T., Takimoto, T., Takabayashi, M., Yamada, S., Yagi, C., Kiryu, Y., Kurimoto, M., Ishikawa, M., Yoshida, A., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.71521
OncoBERT: Context-Aware Modeling of Somatic Mutations for Precision OncologyPreprint
Patkar, S., Auslander, N., Harmon, S. A., Choyke, P. L., & Türkbey, B. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.18.706658
Comprehensive Genomic and Transcriptomic Analysis to Guide Therapy for Patients with Metastatic Solid Tumors
Uzunparmak, B., Su, F., Johnson, A., Shaw, K. R. M., Kong, E., Korkut, A., Xavier, C. B., Yuan, Y., Fowler, N. H., Paradiso, F., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1304
Expanding Opportunities and Evolving Challenges in the Genetic Diagnosis and Genetic Counseling of Hereditary Tumors in Japan
Sakurai, A. (2026) · Springer eBooks · doi:10.1007/978-981-95-6580-1_15
From Biopsy to Biology: Next-Generation Sequencing in Endometrial, Ovarian, and Cervical Carcinoma
Vellone, V. G., Gaggero, G., & Paudice, M. (2026) · Current clinical pathology · doi:10.1007/978-3-032-18790-1_9
Functional Precision Oncology Approach Using Nanoliter Droplet Array for Drug Sensitivity Testing in Lung Cancer
Salarian, M., Schiling, V. L., Muley, T., Allgäeuer, M., Eichhorn, F., Meister, M., Schneider, M. A., & Popova, A. A. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202503761
Differentiation therapy in acute myeloid leukaemia: molecular basis, clinical progress, and future perspectives
Asiri, A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1818483
Quality and safety of research biopsies in oncology clinical trials
Nuciforo, P. G., Ruíz‐Pace, F., Jimenez, J., Comas, R., Fasani, R., Viaplana, C., Sevillano, C., Martinez, P., Serres, X., Rosón, N., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116819
SYNTHESIS-Breast: A prospective early-phase trial of a genetic-interaction- focused computational algorithm in advanced metastatic breast cancerPreprint
Warner, A. B., Solarz, B. B., Belyov, M., Bolanos, V., McCoy, A., Fujii, T., Lee, J.-M., Conlon, K. C., Gomez, M., Redd, B. A., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9522272/v1
Hybrid adenoid cystic carcinoma of the palate with dual features
Sharma, P. N., Pakhale, A. P., Chavhan, A. S., & Hande, A. H. (2026) · BMJ Case Reports · doi:10.1136/bcr-2025-265972
Heterogeneity of Ex Vivo Tumor Responses in Ovarian Cancer Tissues
Maestri, C., Trus, I., Nitiyanandan, R., Kumar, J., Parker, R. J., Tommasi, O. D., Cance, W. G., & Apfel, C. M. (2026) · Cancer Reports · doi:10.1002/cnr2.70554
Reply to: “Genomics-guided therapy in advanced primary liver cancers: A promising yet methodologically challenging landscape”
Campani, C., & Nault, J. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.06.004
Perspectives From an Expert-Guided Discussion on Maximizing the Research Potential of Small Biopsy Tissue
Agrawal, L., Williams, P. M., Moore, H. M., Engel, K. B., Greytak, S. R., Tam, A. L., Killian, J. K., Merrick, D. T., Parchment, R. E., Hamilton, S. R., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-01152
Self-citation
Precision oncology in cholangiocarcinoma integrates molecular taxonomy testing strategies and treatment sequencing
Shi, W., Duan, N., Ma, D., Hao, J., Wei, P., & Li, Z. (2026) · Discover Oncology · doi:10.1007/s12672-026-05129-3
Governing molecular tumor boards: Precision funnel analysis, outcome gap, and a pay-at-result reform framework — Evidence from a nationally mandated programme
Iannopollo, M., & Berti, G. (2026) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2026.100787
CellGPT Map: A Universal Causal Embedding Atlas of Cancer Cells Revealing Therapeutic Similarity beyond Anatomical Origin Article type: Hypothesis and Theory (Perspective)Preprint
Ahmed, A. K. K., & almutairi, K. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7216082
Associations of Age With Tumor Genomic Characteristics in Relapsed/Refractory Cancers Interrogated With the NCI-MATCH Trial Targeted Gene Panel Assay
Sankaran, H., Kotliarov, Y., Zhao, Y., Harris, L. N., Tricoli, J. V., Hamilton, S. R., Temkin, S. M., Karlovich, C., Chang, T.-C., Wang, V., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-01183
Self-citation
Clinical metastatic cancer from initiation to colonization: emerging challenges and breakthroughs
Niu, G., & Hagerling, C. (2026) · Oncogene · doi:10.1038/s41388-026-03944-0
Scoring drug efficacy by integrating drug-induced protein-protein interactions into cellular phenotypic information
Gao, L., Sun, B., Peng, C., Qu, R., Li, S., Huang, Q., Li, X., & Chen, T. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119266
Self-citation
FORESEE: A prospective feasibility trial of functional precision oncology for metastatic breast cancer patientsPreprint
Vaklavas, C., Buys, S. S., Scherer, S. D., Kelley, K. C., Zhou, L., Yang, C.-H., Cortes-Sanchez, E., Butterfield, A., Huang, X., Moos, P. J., et al. (2026) · medRxiv · doi:10.64898/2026.10.10.26365226
The right patient, the right moment, the right therapy: reimagining precision oncology from the bedside
Xu, L., & Lim, B. (2026) · Cancer Metastasis Review · doi:10.1007/s10555-026-10387-2

Authors: Flaherty, K. T., Gray, R. J., Chen, A. P., Li, S., McShane, L. M., Patton, D., Hamilton, S. R., Williams, P. M., Iafrate, A. J., Sklar, J., Mitchell, E. P., Harris, L. N., Takebe, N., Sims, D. J., Coffey, B., Fu, T., Routbort, M., Zwiebel, J. A., Rubinstein, L. V., Little, R. F., Arteaga, C. L., Comis, R., Abrams, J. S., O’Dwyer, P. J., Conley, B. A., & for the NCI-MATCH team
Affiliations: Massachusetts General Hospital (US)
Dana-Farber Cancer Institute (US)
National Institutes of Health (US)
The University of Texas MD Anderson Cancer Center (US)
Frederick National Laboratory for Cancer Research (US)
Harvard University (US)
Yale University (US)
Thomas Jefferson University Hospital (US)
Harold C. Simmons Comprehensive Cancer Center (US)
ECOG-ACRIN Cancer Research Group (US)
Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD
Corresponding author: Flaherty, Keith T.
ORCID: Flaherty, Keith T.
Gray, Robert J.
Chen, Alice P.
Li, Shuli
McShane, Lisa M.
Patton, David
Hamilton, Stanley R.
Williams, P. Mickey
Iafrate, A. John
Sklar, Jeffrey
Mitchell, Edith P.
Harris, Lyndsay N.
Takebe, Naoko
Coffey, Brent
Routbort, Mark
Zwiebel, James A.
Rubinstein, Larry V.
Little, Richard F.
Arteaga, Carlos L.
Abrams, Jeffrey S.
Conley, Barbara A.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2020-11-20
Volume: 38
Issue: 33
Pages: 3883-3894
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.19.03010
PMC: PMC7676882
OpenAlex: W3092241364
Cited by: 294
References: 27
Citations by year: 2026: 35 · 2025: 41 · 2024: 51 · 2023: 68 · 2022: 55 · 2021: 41 · 2020: 3
FWCI: 14.31
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
Locations: Journal of Clinical Oncology (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
The Medicine Forum (submittedVersion, cc-by)
Funders: National Cancer Institute (U10CA180820, UG1CA233337, UG1CA233329, UG1CA233180, UG1CA233341, U10CA180794, UG1CA233302, U24CA196172)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: NCI-MATCH trial, actionable molecular alterations, targeted therapy, molecular profiling, next-generation sequencing, resistance mutations, combination targeted therapy, refractory cancer, urothelial carcinoma, pancreatic cancer, small cell lung cancer
MeSH terms: Adolescent, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Biopsy, Female, Humans, Male, Middle Aged, Neoplasms, Disease Progression, Young Adult, High-Throughput Nucleotide Sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks